PRME
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Prime Medicine, Inc. (PRME) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C (2.3) | B (3.3) | D+ (1.6) | B+ (3.7) | C+ (2.6) | C+ (2.7) |
| 2026-11-07 | D+ (1.7) | C (2.2) | D- (1.0) | B (3.4) | C+ (2.7) | C (2.2) |
| 2026-10-31 | D+ (1.6) | C- (2.1) | D- (1.0) | B- (2.9) | C+ (2.7) | C- (2.1) |
| 2026-10-24 | C- (2.0) | C- (2.1) | D- (0.9) | C+ (2.6) | C+ (2.6) | C- (2.0) |
| 2026-10-17 | C- (2.1) | C- (2.1) | D- (0.9) | C (2.5) | C+ (2.6) | C- (2.0) |